tetano
Editor, Senior Moderator
Am J Case Rep
. 2024 Jun 29:25:e941165.
doi: 10.12659/AJCR.941165. A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments
Flavia Sanmartin[SUP] 1 [/SUP], Eugenia Magrini[SUP] 1 [/SUP], Emanuele Rando[SUP] 1 [/SUP], Paola Del Giacomo[SUP] 2 [/SUP], Alex Dusina[SUP] 2 [/SUP], Elena Matteini[SUP] 1 [/SUP], Andrea Carbone[SUP] 1 [/SUP], Giuseppe Puma[SUP] 1 [/SUP], Gabriele Maria Leanza[SUP] 1 [/SUP], Federico Frondizi[SUP] 1 [/SUP], Idanna Innocenti[SUP] 3 [/SUP], Giuseppe Maiuro[SUP] 2 [/SUP], Flora Marzia Liotti[SUP] 2 [/SUP], Rosaria Santangelo[SUP] 2 [/SUP], Luca Laurenti[SUP] 3 [/SUP], Antonella Cingolani[SUP] 2 [/SUP]
Affiliations
BACKGROUND SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment. This report is of a 67-year-old man with chronic lymphocytic leukemia (CLL), secondary hypogammaglobulinemia, and thrombocytopenia on maintenance therapy with ibrutinib, with persistent SARS-CoV-2 infection unresponsive to antiviral treatment, including remdesivir, nirmatrelvir/ritonavir (Paxlovid), and tixagevimab/cilgavimab (Evusheld). CASE REPORT The patient was admitted to our hospital 3 times. During his first hospitalization, he was treated with 5-day course of remdesivir and intravenous steroids; however, antigen and molecular nasopharyngeal swabs were persistently positive, and he was discharged home. Due to respiratory worsening, he was rehospitalized, and despite being treated initially with tixagevimab/cilgavimab, and subsequently with a remdesivir course of 5 days, SARS-CoV-2 tests remained persistently positive. During his third hospital stay, our patient was subjected to combined therapy with remdesivir and nirmatrelvir/ritonavir for 5 days, obtaining a significant reduction of viral load at both antigen and molecular testing. As an ultimate attempt to achieve a negative status before discharge, a 10-day course of combined remdesivir and nirmatrelvir/ritonavir was administered, with a temporary reduction of viral load, followed by a sudden increase immediately after the discontinuation of Paxlovid. Due to worsening hematological disease and bacterial over-infections, the patient gradually worsened until death. CONCLUSIONS This is an emblematic case of correlation between persistent SARS-CoV-2 infection and immunosuppression status in hematological hosts. In these patients, the viral load remains high, favoring the evolution of the virus, and the immunodeficiency makes it difficult to identify the appropriate therapeutic approach.
. 2024 Jun 29:25:e941165.
doi: 10.12659/AJCR.941165. A 67-Year-Old Man with Chronic Lymphocytic Leukemia (CLL) on Maintenance Therapy with Ibrutinib with Persistent SARS-CoV-2 Infection Unresponsive to Antiviral Treatments
Flavia Sanmartin[SUP] 1 [/SUP], Eugenia Magrini[SUP] 1 [/SUP], Emanuele Rando[SUP] 1 [/SUP], Paola Del Giacomo[SUP] 2 [/SUP], Alex Dusina[SUP] 2 [/SUP], Elena Matteini[SUP] 1 [/SUP], Andrea Carbone[SUP] 1 [/SUP], Giuseppe Puma[SUP] 1 [/SUP], Gabriele Maria Leanza[SUP] 1 [/SUP], Federico Frondizi[SUP] 1 [/SUP], Idanna Innocenti[SUP] 3 [/SUP], Giuseppe Maiuro[SUP] 2 [/SUP], Flora Marzia Liotti[SUP] 2 [/SUP], Rosaria Santangelo[SUP] 2 [/SUP], Luca Laurenti[SUP] 3 [/SUP], Antonella Cingolani[SUP] 2 [/SUP]
Affiliations
- PMID: 38943241
- DOI: 10.12659/AJCR.941165
BACKGROUND SARS-CoV-2 infection can persist in immunocompromised patients with hematological malignancies, despite antiviral treatment. This report is of a 67-year-old man with chronic lymphocytic leukemia (CLL), secondary hypogammaglobulinemia, and thrombocytopenia on maintenance therapy with ibrutinib, with persistent SARS-CoV-2 infection unresponsive to antiviral treatment, including remdesivir, nirmatrelvir/ritonavir (Paxlovid), and tixagevimab/cilgavimab (Evusheld). CASE REPORT The patient was admitted to our hospital 3 times. During his first hospitalization, he was treated with 5-day course of remdesivir and intravenous steroids; however, antigen and molecular nasopharyngeal swabs were persistently positive, and he was discharged home. Due to respiratory worsening, he was rehospitalized, and despite being treated initially with tixagevimab/cilgavimab, and subsequently with a remdesivir course of 5 days, SARS-CoV-2 tests remained persistently positive. During his third hospital stay, our patient was subjected to combined therapy with remdesivir and nirmatrelvir/ritonavir for 5 days, obtaining a significant reduction of viral load at both antigen and molecular testing. As an ultimate attempt to achieve a negative status before discharge, a 10-day course of combined remdesivir and nirmatrelvir/ritonavir was administered, with a temporary reduction of viral load, followed by a sudden increase immediately after the discontinuation of Paxlovid. Due to worsening hematological disease and bacterial over-infections, the patient gradually worsened until death. CONCLUSIONS This is an emblematic case of correlation between persistent SARS-CoV-2 infection and immunosuppression status in hematological hosts. In these patients, the viral load remains high, favoring the evolution of the virus, and the immunodeficiency makes it difficult to identify the appropriate therapeutic approach.